Tissue plasminogen activator for thrombolytic therapy: expectation versus reality.
作者信息
Gaffney P J
机构信息
Division of Haematology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire.
出版信息
J R Soc Med. 1992 Nov;85(11):692-8. doi: 10.1177/014107689208501112.
Abstract
摘要
相似文献
1
Tissue plasminogen activator for thrombolytic therapy: expectation versus reality.用于溶栓治疗的组织型纤溶酶原激活剂：期望与现实
J R Soc Med. 1992 Nov;85(11):692-8. doi: 10.1177/014107689208501112.
2
Trial design in the thrombolytic age.
Lancet. 1991 Mar 9;337(8741):610-1. doi: 10.1016/0140-6736(91)91671-g.
3
Enrolment in trials of thrombolysis.溶栓试验的入组情况。
Lancet. 1990 Oct 27;336(8722):1069-70. doi: 10.1016/0140-6736(90)92540-x.
4
[Tissue plasminogen activator is the best thrombolytic agent].
Arq Bras Cardiol. 1994 Jul;63(1):57-8.
5
TNK-tPA: a new thrombolytic for treatment of acute myocardial infarction.替奈普酶：一种用于治疗急性心肌梗死的新型溶栓剂。
S D J Med. 2000 May;53(5):185-6.
6
ER TIMI-19: testing the reality of prehospital thrombolysis.
J Emerg Med. 2000 Oct;19(3 Suppl):21S-25S. doi: 10.1016/s0736-4679(00)00251-1.
7
GUSTO, TIMI and the case for rapid reperfusion.全球急性冠状动脉综合征（GUSTO）、心肌梗死溶栓治疗（TIMI）与快速再灌注疗法的依据
Acta Cardiol. 1994;49(1):1-8.
8
Fibrin-selective thrombolytic therapy for acute myocardial infarction.
Circulation. 1996 Mar 1;93(5):857-65. doi: 10.1161/01.cir.93.5.857.
9
Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part I.重组组织型纤溶酶原激活剂：急性心肌梗死临床应用的当前概念与指南。第一部分。
Am Heart J. 1991 Jan;121(1 Pt 1):220-44. doi: 10.1016/0002-8703(91)90986-r.
10
Suspended judgment. Thrombolytic therapy for acute myocardial infarction in the United States: we started on the high road.暂缓判断。美国急性心肌梗死的溶栓治疗：我们起步很高。
Control Clin Trials. 1992 Aug;13(4):253-5. doi: 10.1016/0197-2456(92)90009-o.
本文引用的文献
1
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.用人外源性（组织型）纤溶酶原激活剂对实验性颈静脉血栓形成的家兔进行溶栓治疗。激活剂分子形式和剂量、血栓形成时间以及给药途径的影响
J Clin Invest. 1983 Feb;71(2):368-76. doi: 10.1172/jci110778.
2
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.组织型纤溶酶原激活剂用于进展性心肌梗死患者的冠状动脉溶栓治疗。
N Engl J Med. 1984 Mar 8;310(10):609-13. doi: 10.1056/NEJM198403083101001.
3
Tissue plasminogen activator: chemical and physiological aspects.组织型纤溶酶原激活剂：化学与生理学方面
Semin Thromb Hemost. 1984 Jan;10(1):6-17. doi: 10.1055/s-2007-1004403.
4
Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin.
Proc Soc Exp Biol Med. 1971 Oct;138(1):277-80. doi: 10.3181/00379727-138-35878.
5
Thrombolytic therapy: current status (2).溶栓治疗：现状（2）
N Engl J Med. 1988 Jun 16;318(24):1585-95. doi: 10.1056/NEJM198806163182406.
6
Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.静脉注射组织型纤溶酶原激活剂与急性心肌梗死的梗死面积、左心室功能及生存率
BMJ. 1988 Nov 26;297(6660):1374-9. doi: 10.1136/bmj.297.6660.1374.
7
Effectors of the activation of human [Glu1]plasminogen by human tissue plasminogen activator.人组织型纤溶酶原激活物激活人[Glu1]纤溶酶原的效应物。
Biochemistry. 1988 Aug 23;27(17):6522-8. doi: 10.1021/bi00417a049.
8
Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.一种嵌合型纤溶酶原激活剂的特性，该激活剂由组织型纤溶酶原激活剂的1至274个氨基酸和单链尿激酶型纤溶酶原激活剂的138至411个氨基酸组成。
J Biol Chem. 1988 Dec 15;263(35):19083-91.
9
Roles for chloride ion and fibrinogen in the activation of [Glu1]plasminogen in human plasma.氯离子和纤维蛋白原在人血浆中激活[Glu1]纤溶酶原的作用。
Proc Natl Acad Sci U S A. 1988 May;85(10):3595-8. doi: 10.1073/pnas.85.10.3595.
Zotero 插件